Patient Guide: A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 79 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05967689
Status: 🟢 Enrolling Now
Condition: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Phase: PHASE2

Where You Can Participate

This study is available at 79 locations across the country.

Top locations include:
  • • Birmingham, Alabama
  • • Duarte, California
  • • Boston, Massachusetts
  • • And 76 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. - Join Clinical Trial NCTNCT05967689

How to Join This Clinical Trial - NCTNCT05967689

Learn how to participate in this PHASE2 trial studying an investigational therapy for Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT05967689 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 79 locations. Find a study site near you:

Clinical Research Site

Birmingham, Alabama 35294 - United States

Status: WITHDRAWN

Clinical Research Site

Duarte, California 91010 - United States

Status: RECRUITING

Clinical Research Site

Boston, Massachusetts 02215 - United States

Status: RECRUITING

Clinical Research Site

Las Vegas, Nevada 89169 - United States

Status: RECRUITING

Clinical Research Site

Basking Ridge, New Jersey 07920 - United States

Status: RECRUITING

Clinical Research Site

Middletown, New Jersey 07748 - United States

Status: RECRUITING

Clinical Research Site

Montvale, New Jersey 07645 - United States

Status: RECRUITING

Clinical Research Site

Commack, New York 11725 - United States

Status: RECRUITING

Clinical Research Site

Harrison, New York 10604 - United States

Status: RECRUITING

Clinical Research Site

Long Island City, New York 11101 - United States

Status: RECRUITING

And 69 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships